Search
Patexia Research
Case number 1:21-cv-01707

Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Ltd. et al > Documents

Date Field Doc. No.Description (Pages)
Nov 23, 2022 60 Amended Complaint* (1)
Aug 5, 2022 43 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Defendants Aurobindo Pharma USA Inc. and Aurobindo Pharma Ltd.'s Initial Invalidity Contentions filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Hitch, Cortlan)
Aug 3, 2022 42 SO ORDERED (1)
Docket Text: SO ORDERED, re [40] STIPULATION TO EXTEND TIME for Defendants to serve initial invalidity contentions to August 5, 2022 filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd. Signed by Judge Mitchell S. Goldberg on 08/03/2022. (smg)
Aug 3, 2022 41 Protective Order (25)
Docket Text: PROTECTIVE ORDER. Signed by Judge Mitchell S. Goldberg on 08/03/2022. (smg)
Jul 27, 2022 40 Stipulation to EXTEND Time (1)
Docket Text: STIPULATION TO EXTEND TIME for Defendants to serve initial invalidity contentions to August 5, 2022 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Hitch, Cortlan)
Jul 15, 2022 39 Proposed Order (25)
Docket Text: PROPOSED ORDER -- Protective Order -- by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Jul 14, 2022 38 Order (1)
Docket Text: ORDER granting D.I. [35] STIPULATION TO EXTEND TIME for the parties to file the Proposed Protective Order to July 15, 2022 filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd. Signed by Judge Mitchell S. Goldberg on 07/14/2022. (smg)
Jul 11, 2022 37 Notice of Service (3)
Docket Text: NOTICE OF SERVICE of (1) First Set of Requests for Production (Nos. 1-65); and (2) First Set of Interrogatories (Nos. 1-10) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Jul 7, 2022 36 Notice of Service (3)
Docket Text: NOTICE OF SERVICE of Initial Infringement Claim Charts filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Jul 5, 2022 35 Stipulation to EXTEND Time (1)
Docket Text: STIPULATION TO EXTEND TIME for the parties to file the Proposed Protective Order to July 15, 2022 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Hitch, Cortlan)
Jul 1, 2022 34 Stipulation and Order (1)
Docket Text: STIPULATION AND ORDER for Extension of Time re - D.I. [33]. Time to file the proposed protective order shall be extended to July 5, 2022. Signed by Judge Mitchell S. Goldberg on 7/1/2022. (srs)
Jun 23, 2022 33 Stipulation to EXTEND Time (1)
Docket Text: STIPULATION TO EXTEND TIME for the parties to file the Proposed Protective Order to July 5, 2022 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth)
Jun 13, 2022 32 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of core technical documents filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Dorsney, Kenneth)
May 27, 2022 31 Notice of Service (3)
Docket Text: NOTICE OF SERVICE of (1) Plaintiff Azurity Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Rule 26(a)(1) and (2) Plaintiff Azurity Pharmaceuticals, Inc.'s Identification of Accused Products and Asserted Patents Pursuant to Paragraph 4(a) of the Delaware Default Standard for Discovery - filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
May 26, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Evan T. Sumner for Azurity Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
May 25, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Natalie J. Morgan for Azurity Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
May 24, 2022 30 Scheduling Order (13)
Docket Text: SCHEDULING ORDER: Joinder of Parties due by 1/6/2023. Amended Pleadings due by 1/6/2023. Fact Discovery completed by 2/3/2023. Opening Expert Reports due by 4/4/2023. Rebuttal Expert Reports due by 5/4/2023. Status Report due by 1/6/2023. Tutorial on the technology due by 9/16/2022. Claim Construction Opening Brief due by 9/22/2022. Claim Construction Answering Brief due by 10/13/2022. Claim Construction Reply Brief due by 10/27/2022. Claim Construction Surreply Brief due by 11/10/2022. Joint Claim Construction Brief due by 11/17/2022. A Markman Hearing is set for 12/13/2022 at 10:00 AM at a location to be determined before Judge Mitchell S. Goldberg. A Pretrial Conference is set for 10/23/2023 at 10:00 AM at a location to be determined before Judge Mitchell S. Goldberg. A 5-day Bench Trial is set for 11/13/2023 at 09:00 AM at a location to be determined before Judge Mitchell S. Goldberg. (See Order for further deadlines). Signed by Judge Mitchell S. Goldberg on 5/24/2022. (nmg)
May 20, 2022 29 Notice of Service (3)
Docket Text: NOTICE OF SERVICE of Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
May 20, 2022 28 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of (1) Aurobindo Pharma USA Inc. and Aurobindo Pharma Ltd.'s Paragraph 3 Initial Disclosures and; (2) Aurobindo Pharma USA Inc. and Aurobindo Pharma Ltd.'s Rule 26(a)(1) Initial Disclosures filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Dorsney, Kenneth)
May 13, 2022 27 Proposed Order (13)
Docket Text: PROPOSED ORDER -- Scheduling Order -- by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
May 3, 2022 26 Order on Motion to Appear Pro Hac Vice (2)
Docket Text: ORDER granting [24] Motion to Appear Pro Hac Vice. Signed by Judge Mitchell S. Goldberg on 5/3/22. (mal)
May 2, 2022 25 Transcript (57)
Docket Text: Official Transcript of Status Hearing held on 4/25/2022 before Judge Mitchell S. Goldberg. Court Reporter/Transcriber Michael T. Keating, Phone: (609) 440-2177. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 5/23/2022. Redacted Transcript Deadline set for 6/2/2022. Release of Transcript Restriction set for 8/1/2022. Associated Cases: 1:18-cv-01962-MSG et al.(nmg)
Apr 28, 2022 24 Motion for Leave to Appear Pro Hac Vice (4)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Evan T. Sumner - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Apr 25, 2022 23 Order on Motion to Appear Pro Hac Vice (1)
Docket Text: ORDER granting [22] Motion to Appear Pro Hac Vice. Signed by Judge Mitchell S. Goldberg on 4/25/2022. (cna, )
Apr 25, 2022 N/A Status Conference (0)
Docket Text: Minute Entry for proceedings held before Judge Mitchell S. Goldberg - Zoom Status Conference held on 4/25/2022. (Court Reporter Jimmy Cruz.) Associated Cases: 1:18-cv-01962-MSG et al. (nmg)
Apr 22, 2022 22 Motion for Leave to Appear Pro Hac Vice (2)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Lina Genovesi - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth)
Apr 13, 2022 21 Status Report (9)
Docket Text: Joint STATUS REPORT by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 30, 2022 20 Order (2)
Docket Text: ORDER, A status conference will be held on the record, by video conference, on Monday, April 25, 2022, at 3:00 p.m. Chambers will contact the parties with details for joining the video conference. Counsel for all parties shall meet and confer and, within fourteen (14) days of the date of this Order, file a joint letter summarizing the status of each of the above cases. Signed by Judge Mitchell S. Goldberg on 3/30/2022. Associated Cases: 1:18-cv-01962-MSG et al. (nmg)
Mar 23, 2022 19 Order on Motion to Appear Pro Hac Vice (2)
Docket Text: ORDER that counsels motion for admission pro hac vice [18] of Wendy L. Devine, Kristina M. Hanson and Natalie J. Morgan is granted. Signed by Judge Mitchell S. Goldberg on 3/23/22. (mal)
Mar 21, 2022 18 Motion for Leave to Appear Pro Hac Vice (6)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Wendy L. Devine, Kristina M. Hanson and Natalie J. Morgan - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 2, 2022 N/A Case Assigned/Reassigned (0)
Docket Text: Case Reassigned to Judge Mitchell S. Goldberg of the United States District Court for the Eastern District of Pennsylvania. Please include the initials of the Judge (MSG) after the case number on all documents filed. Associated Cases: 1:18-cv-01962-MSG, 1:19-cv-01067-MSG, 1:19-cv-02100-MSG, 1:20-cv-01256-MSG, 1:21-cv-00196-MSG, 1:21-cv-01286-MSG, 1:21-cv-01455-MSG, and 1:21-cv-01707-MSG. (rjb)
Feb 25, 2022 17 Status Report (8)
Docket Text: Joint STATUS REPORT by Azurity Pharmaceuticals, Inc., Silvergate Pharmaceuticals, Inc.. (Dellinger, Megan)
Feb 23, 2022 N/A Order (0)
Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that in anticipation of reassignment of these cases (C.A. Nos. 18-1962, 19-1067, 19-2100, 21-196, 21-1286, 21-1455, 21-1707) to another judge, the parties shall meet and confer and, no later than February 25, submit a joint status report (one that collectively addresses all of these related cases), advising the Court of the following (in addition to anything else the parties wish to report): (i) whether trial has occurred and/or is scheduled to occur and if so, when; (ii) whether a preliminary injunction motion has been litigated and whether any preliminary injunction motion is anticipated; (iii) the date of expiration of any regulatory stay, if applicable; and (iv) the status of any pending motions, or any motions the parties anticipate filing, and the urgency (if any) of such motions. ORDERED by Judge Leonard P. Stark on 2/23/22. Associated Cases: 1:18-cv-01962-LPS et al. (ntl)
Feb 18, 2022 15 Answer to Counterclaim (10)
Docket Text: ANSWER to [12] Answer to Complaint, Counterclaim -- Answer to Counterclaims -- by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Jan 27, 2022 14 Stipulation to EXTEND Time (1)
Docket Text: STIPULATION TO EXTEND TIME for plaintiff to respond to defendants' counterclaims (D.I. 12) to February 18, 2022 - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Jan 27, 2022 N/A SO ORDERED (0)
Docket Text: SO ORDERED, re [14] STIPULATION TO EXTEND TIME for plaintiff to respond to defendants' counterclaims (D.I. 12) to February 18, 2022 filed by Azurity Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 1/27/22. (ntl)
Jan 7, 2022 13 Disclosure Statement (2)
Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth)
Jan 7, 2022 12 Answer to Complaint (30)
Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Azurity Pharmaceuticals, Inc. by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Dorsney, Kenneth)
Dec 27, 2021 N/A SO ORDERED (0)
Docket Text: SO ORDERED, re [11] MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd. Signed by Judge Leonard P. Stark on 12/27/21. (ntl)
Dec 27, 2021 N/A SO ORDERED (0)
Docket Text: SO ORDERED, re [10] STIPULATION TO EXTEND TIME for Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. to answer, move or otherwise respond to the Complaint to January 10, 2022 filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd. Signed by Judge Leonard P. Stark on 12/27/21. (ntl)
Dec 23, 2021 11 Motion for Leave to Appear Pro Hac Vice (4)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth)
Dec 22, 2021 10 Stipulation to EXTEND Time (1)
Docket Text: STIPULATION TO EXTEND TIME for Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. to answer, move or otherwise respond to the Complaint to January 10, 2022 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth)
Dec 8, 2021 9 Affidavit of Service (10)
Docket Text: AFFIDAVIT of Service for Summons, Complaint and related papers served on Aurobindo Pharma Ltd. on December 8, 2021, filed by Azurity Pharmaceuticals, Inc.. (Raucci, Anthony)
Dec 8, 2021 N/A Case Assigned/Reassigned (0)
Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb)
Dec 7, 2021 8 Summons Returned Executed (2)
Docket Text: SUMMONS Returned Executed by Azurity Pharmaceuticals, Inc.. Aurobindo Pharma USA, Inc. served on 12/7/2021, answer due 12/28/2021. (Dellinger, Megan)
Dec 2, 2021 7 Summons Issued (2)
Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma Ltd. on 12/2/2021.(srs)
Dec 2, 2021 6 Summons Issued (2)
Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma USA, Inc. on 12/2/2021. (srs)
Dec 2, 2021 5 Disclosure Statement (1)
Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent CutisPharma Intermediate Holdings Inc. for Azurity Pharmaceuticals, Inc. filed by Azurity Pharmaceuticals, Inc. (srs)
Dec 2, 2021 4 Patent/Trademark Report to Commissioner (1)
Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,786,482 B2 ;10,918,621 B2 ;11,040,023 B2. (srs)
Dec 2, 2021 3 ANDA Form (1)
Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: October 19, 2021. Date of Expiration of Patent: March 25, 2036.Thirty Month Stay Deadline: April 19, 2024. (srs)
Dec 2, 2021 2 Magistrate Consent Forms (3)
Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs)
Dec 2, 2021 1 Civil Cover Sheet (2)
Dec 2, 2021 1 Exhibit A-C (84)
Dec 2, 2021 1 Complaint* (1)
Dec 2, 2021 1 Main Document (12)
Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3755006.) - filed by Azurity Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit A-C, # (2) Civil Cover Sheet)(srs)
Menu